06 // finding the paper behind a claim
Which papers support the Sermorelin findings you read?
Sermorelin is an injected drug researched for its effects on growth-hormone release. This page helps you find the papers and ask whether their findings fit your health.
Which Sermorelin papers concern the question you want answered?
Small adult studies leave strength and lasting safety uncertain. Children's studies measured height. Numbered links identify the papers used here. Bring a relevant paper's name and number to your visit.
I'd ask which paper measured the change you hope to notice.
Khorram's 1997 study [9] and Vittone's 1997 work [10] concern older adults. Both measured hormone changes more clearly than lasting gains in everyday health. Bartke's chapter in Endotext, a medical reference book, discusses growth hormone during aging [21]. The hormone helps maintain adult bone and muscle. You can't assume that raising the level will make you feel stronger.
The children's papers aren't about this later stage of life. Thorner's 1996 study enrolled 110 children before puberty with low hormone for no known reason [3]. Kirk's 1994 work followed unusually short children [4]. Prakash and Goa reviewed gland testing and growth treatment in 1999 [6]. Those findings don't establish stronger muscles in later life.
Grossman's 1984 work helps answer why a low hormone reading needs more investigation. A weak message from the brain differed from a gland unable to make enough hormone [8]. The 1988 Thorner-Vance review [22] helps you ask what growth hormone normally does in your body. That 1988 review doesn't show that Sermorelin would improve your health now. Their 2008 review explains drugs that prompt hormone release [7]. Reviews aren't proof that treatment would help you.
Frohman's 1994 work measured how quickly the drug left blood [5]. Ishida's 2020 review explains why growth-hormone release can continue afterward [12]. Vance's 1986 review covers the gland releasing less hormone with a constant drug supply [18]. These papers can help you ask why the doctor proposes particular test times.
The other drugs were tested for other questions. Raun's 1998 work examined ipamorelin's effects on hormone release [14]. Falutz's 2010 work tested tesamorelin for fat deep inside the belly in people with HIV [13]. HIV is a virus that damages immune defenses. Esposito studied changes that slowed related drugs' breakdown in 2003 [16]. Ishida reviewed combinations using different actions in 2020 [12][15].
FDA and RxList information describes the older Sermorelin brand's history [17]. Yuen's 2019 guidance concerns adults with too little growth hormone [19]. Ratku's 2017 review discusses shots supplying growth hormone directly [20]. That old approval doesn't establish approval for products offered now. Findings about growth-hormone shots don't prove Sermorelin would help you.
The 1984 work checks the gland's response [8]. Children's 1980s-1990s studies measured growth [3][4]. Reviews explain hormone release [7][22]; Ishida compares related drugs [12]. Ask which findings answer your health question.
Can you read a Sermorelin study without paying for the paper?
Some older papers cost money to read in full. PubMed is a service that lists medical papers and often gives a free short summary. The author names, journal and year help you identify the paper. Its number helps find the same article again. The number's meaning isn't something you need for your visit.
A free summary may still leave an important question unanswered.
Full papers are linked where they're freely available. For some paid journal articles, the link leads to the public summary. That summary gives the topic and findings, with fewer details about the tests and who took part. Before paying to read a paper, ask your doctor which missing detail could affect the choice you're discussing, because a short summary can't give every detail about the tests or the people studied.

How can you judge whether a Sermorelin paper applies to you?
A study can be sound yet answer a question different from yours. First ask who received the drug, how long they were followed and what actually changed. A child's height doesn't establish an older man's ability to lift or walk.
Ask who was studied and which changes were actually measured.
Children's studies tested growth, hormone levels and safety in particular hormone problems. Researchers measured the speed of growth in children or the hormone response following a test shot [3][4][6]. Those are findings about children, rather than proof of a benefit for adults.
Khorram's 1997 study [9] and Vittone's 1997 study [10] enrolled healthy older adults in small groups. Blood readings changed more clearly than lasting health benefits. Ask whether people with your age and illnesses were studied, because a higher hormone reading isn't proof that daily work would become easier for you.
Other papers mainly describe how the drug works. Thorner-Vance reviewed growth-hormone release [7][22]. Vance discussed weaker release with a constant drug supply [18]. Grossman checked the gland's response [8]. Frohman measured the drug leaving blood [5]. Ishida reviewed release and combinations [12][15]. Esposito studied slower breakdown [16]; Raun studied ipamorelin's action [14]. The Thorner group's 2008 review covered lab work and studies with people [7]. These papers explain drug effects without proving gains in your everyday health.
- Sermorelin acetate (GHRH 1-29 NH2) — synthetic 29-amino-acid N-terminal fragment of human growth hormone-releasing hormone; molecular weight 3357.9 Da; sequence Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2. Reference compound characterization, drug monograph. ↗
- Mechanism note: GHRH receptor (GHRHR) is a class B G-protein-coupled receptor on anterior pituitary somatotrophs; activation couples to Gs-alpha / adenylyl cyclase / cAMP / PKA, driving GH gene transcription, synthesis, and pulsatile release; hepatic IGF-1 induction is downstream of GH. See Thorner et al., 2008 (citation 7) for the canonical mechanism synthesis. ↗
- Thorner MO, Rochiccioli P, Colle M, Lanes R, Grunt J, Galazka A, Landy H, Eengrand P, Shah S. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. international multi-site study group. J Clin Endocrinol Metab. 1996;81(3):1189-1196. ↗
- Kirk JM, Trainer PJ, Majrowski WH, et al. Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity. J Clin Endocrinol Metab. 1994;79(4):1248-1252. ↗
- Frohman LA, Downs TR, Heimer EP, Felix AM. Incorporation of D-Ala2 in growth hormone-releasing hormone-(1-29)-NH2 increases the half-life and decreases metabolic clearance in normal men. J Clin Endocrinol Metab. 1994. ↗
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. ↗
- Thorner MO, Vance ML, Hartman ML, et al. Growth-hormone-releasing hormone: clinical and basic studies. J Neuroendocrinol. 2008. ↗
- Grossman A, Savage MO, Lytras N, Preece MA, Sueiras-Diaz J, Coy DH, Rees LH, Besser GM. Responses to analogues of growth hormone-releasing hormone in normal subjects, and in growth-hormone deficient children and young adults. Clin Endocrinol (Oxf). 1984. ↗
- Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab. 1997;82(5):1472-1479. ↗
- Vittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, Stevens T, Bellantoni MF, Rogers MA, Baumann G, Roth J, Harman SM, Spencer RG. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997. ↗
- Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development (companion review). ↗
- Ishida J, Saitoh M, Ebner N, Springer J, Anker SD, von Haehling S. Growth hormone secretagogues: history, mechanism of action, and clinical development. JCSM Rapid Communications. 2020. ↗
- Falutz J, Potvin D, Mamputu JC, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. J Clin Endocrinol Metab. 2010. ↗
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. ↗
- Combined-stimulus pharmacology: GHRH analog (sermorelin class) + ghrelin-receptor agonist (GHRP/ipamorelin class) produces supra-additive GH release; see Ishida et al., 2020 (citation 12) for the modern synthesis of GHRH + GHRP combined-stimulus pharmacology. ↗
- Esposito P, Barbero L, Caccia P, Caliceti P, D'Antonio M, Piquet G, Veronese FM. PEGylation of growth hormone-releasing hormone (GRF) analogues. Adv Drug Deliv Rev. 2003. ↗
- Sermorelin acetate drug monograph: FDA approval of sermorelin acetate for pediatric idiopathic GH deficiency (1997); voluntary US market discontinuation (2008) for commercial — not safety — reasons; compounded preparations remain available under 503A/503B framework. ↗
- Vance ML. Growth-Hormone-Releasing Hormone: A Clinical Update. Ann Intern Med. 1986;105(3):447-454. ↗
- Yuen KCJ, Biller BMK, Radovick S, et al. AACE/ACE Guidelines for Management of Growth Hormone Deficiency in Adults and Patients Transitioning from Pediatric to Adult Care. Endocr Pract. 2019. ↗
- Ratku B, Sebestyén V, Erdei A, et al. Treatment of adult growth hormone deficiency with human recombinant growth hormone: update on current evidence and critical review. Endocrine. 2017. ↗
- Bartke A, Brown-Borg H, et al. Growth Hormone in Aging. Endotext (NCBI Bookshelf). Continuously updated. ↗
- Thorner MO, Vance ML. Growth hormone, 1988. J Clin Invest. 1988;82(3):745-747. ↗